53 related articles for article (PubMed ID: 16481384)
41. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.
Bongers ML; Coupé VM; Jansma EP; Smit EF; Uyl-de Groot CA
Pharmacoeconomics; 2012 Jan; 30(1):17-34. PubMed ID: 22201521
[TBL] [Abstract][Full Text] [Related]
42. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Noble S; Goa KL
Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
[TBL] [Abstract][Full Text] [Related]
43. Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
Shepherd FA
Semin Oncol; 1999 Feb; 26(1 Suppl 4):3-11. PubMed ID: 10201515
[TBL] [Abstract][Full Text] [Related]
44. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
45. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Bunn PA; Kelly K
Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
[TBL] [Abstract][Full Text] [Related]
46. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
47. Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
di Noia V; D'Argento E; Pilotto S; Grizzi G; Caccese M; Iacovelli R; Tortora G; Bria E
Expert Opin Biol Ther; 2018 Sep; 18(9):937-945. PubMed ID: 30075697
[TBL] [Abstract][Full Text] [Related]
48. [Pharmacogenetics in tumors of the lung].
Altavilla G; Marabello G
Suppl Tumori; 2004; 3(2):S31-2. PubMed ID: 15067962
[No Abstract] [Full Text] [Related]
49. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer.
Dooms CA; Lievens YN; Vansteenkiste JF
Eur Respir J; 2006 May; 27(5):895-901. PubMed ID: 16481384
[TBL] [Abstract][Full Text] [Related]
50. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
51. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer.
Dranitsaris G; Cottrell W; Evans WK
Curr Opin Oncol; 2002 Jul; 14(4):375-83. PubMed ID: 12130919
[TBL] [Abstract][Full Text] [Related]
53. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
